We know Sterile Injectable Formulations
From first formulation to sterile clinical vial.
When oral delivery is not an option, precision and sterility are everything.
Parenteral formulations are among the most demanding drug products to develop and manufacture. Administered directly into the body — intravenously, intramuscularly, or subcutaneously — they bypass the gastrointestinal tract entirely, placing the drug immediately into systemic circulation with no absorption barrier and no margin for formulation error. Sterility is non-negotiable. Process control is critical. And the path from formulated bulk to a filled, released vial ready for a clinical site demands tight integration between formulation science, analytical development, and aseptic manufacturing.
Parenteral routes are chosen when speed of onset matters, when oral delivery is not feasible, when precise and predictable systemic exposure is required, or when the molecule itself demands it — as is increasingly the case with complex biologics, poorly soluble small molecules, and advanced nanomedicine modalities.
At Ardena, we support the development and GMP clinical manufacturing of liquid parenteral drug products — from sterile solutions to nanoparticle-based formulations — with a fully integrated platform that takes your compound from early formulation concept through to a sterile, vialed clinical product.
WHAT WE OFFER
Formulation Precision for Complex Parenteral APIs
Developing a stable, injectable sterile solution requires far more than dissolving an API in water for injection. pH, tonicity, excipient compatibility, container–closure interaction, and degradation pathways under sterilisation conditions all require careful evaluation — particularly for APIs at the edges of solubility, stability, or compatibility.
Ardena’s formulation scientists bring deep expertise in parenteral solution development, designing formulations that are stable through their intended shelf life, compatible with the sterilisation and fill–finish process, and manufacturable under GMP conditions. Formulation development is conducted with scalability in mind from the outset, ensuring that the process defined at laboratory scale transfers reliably to clinical manufacturing.
Advanced Delivery for Complex and Poorly Soluble Molecules
Nanoparticulate systems represent one of the most rapidly evolving areas of parenteral drug product development — and one of Ardena’s key areas of expertise. Where conventional solution formulations are not achievable due to poor solubility, instability, or the need for controlled or targeted delivery, engineered nanoscale carriers offer a viable and increasingly clinically validated alternative.
Ardena has extensive experience in the development and GMP manufacturing of nanomedicines across a range of nanoparticle architectures and drug modalities, including lipid-based nanoparticles, polymeric nanoparticles, and nanoparticulate formulations of small molecules and biologics.
The advantages these systems offer — improved solubilisation of poorly soluble APIs, protection of sensitive molecules from degradation, the potential for controlled release or tissue targeting — make them particularly relevant for oncology, rare disease, and complex molecule programmes where conventional formulation strategies fall short.
From Lab to GMP — Without Losing What You Built
The transition from a laboratory-developed parenteral formulation to a GMP-manufactured clinical batch is where many programmes encounter their first serious setbacks. Processes that perform well at small scale can behave unpredictably when equipment geometry changes, mixing dynamics shift, or batch size increases by an order of magnitude.
Ardena’s process development approach is designed to prevent these surprises. Critical process parameters are characterised systematically at lab scale, scale-up principles are applied early, and GMP manufacturing processes are designed to be robust across the batch sizes required for clinical supply — not just optimised for the conditions of the development laboratory.
Sterile Vials, Clinical-Ready — Under Isolator Technology
The final step between a formulated bulk drug product and a clinical-ready parenteral is aseptic fill and finish — and it is a step that demands the highest standards of environmental control, process validation, and in-process monitoring.
Ardena provides aseptic fill and finish capabilities for clinical supply using isolator technology, which provides the highest level of sterility assurance available for vial filling operations. Our cleanroom environment and aseptic processing setup support flexible batch sizes appropriate for Phase I and Phase II clinical supply, ensuring that small and mid-scale clinical batches receive the same standard of sterility assurance as large commercial runs.
Key capabilities:
- Isolator-based aseptic vial filling for maximum sterility assurance
- Controlled cleanroom environment throughout the fill–finish process
- Flexible batch sizes — designed for the realities of early clinical development
- Full in-process controls, 100% vial inspection, and analytical release testing
- Seamless handoff between formulation development and fill–finish
INTEGRATED DEVELOPMENT AND MANUFACTURING
One team. One program. No handoffs.
What distinguishes our parenteral offering is not any single capability — it is the integration between them. Formulation development, analytical method development, process development, and aseptic fill and finish are a connected workflow managed by scientists and engineers who work together from day one. Analytical methods developed alongside the formulation. Manufacturing processes designed with fill-finish in mind from the start. A single point of accountability from first formulation concept to sterile, released clinical product. For programmes under timeline and resource pressure, this model reduces coordination overhead, compresses development timelines, and eliminates the gaps that arise when development and manufacturing are handled separately.
Integrated development and GMP manufacturing
formulation, analytics, process development, and aseptic fill and finish under one roof, managed as a single programme
Nanomedicine expertise
proven capabilities in lipid nanoparticles, polymeric nanoparticles, and nanoparticulate formulations of small molecules and biologics
Isolator-based fill and finish
the highest available sterility assurance standard for clinical vial filling
Scalable from concept to clinic
processes designed for clinical supply from the first development experiment, not retrofitted at scale-up
